Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Morgan, P, Woolacott, N, Biswas, M et al. (3 more authors) (2017) Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35 (9). pp. 909-919. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: (c) 2017, Crown Copyright. This is an author produced version of a paper published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Overall Survival; Pemetrexed; Anaplastic Lymphoma Kinase; Crizotinib; Evidence Review Group.
Dates:
  • Published (online): 24 March 2017
  • Published: September 2017
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Translational Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 18 Jun 2018 15:31
Last Modified: 23 Jul 2018 17:45
Status: Published
Publisher: Springer
Identification Number: https://doi.org/10.1007/s40273-017-0497-1
Related URLs:

Share / Export

Statistics